GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » 3-Year FCF Growth Rate

Oncolytics Biotech (Oncolytics Biotech) 3-Year FCF Growth Rate : 8.40% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech 3-Year FCF Growth Rate?

Oncolytics Biotech's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.06.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 8.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 14.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Oncolytics Biotech was 33.20% per year. The lowest was -60.70% per year. And the median was 4.75% per year.


Competitive Comparison of Oncolytics Biotech's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Oncolytics Biotech's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's 3-Year FCF Growth Rate falls into.



Oncolytics Biotech 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Oncolytics Biotech  (NAS:ONCY) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Oncolytics Biotech 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.